Literature DB >> 15515404

Physiology and pathophysiology of the 5-HT3 receptor.

L Färber1, U Haus, M Späth, S Drechsler.   

Abstract

The 5-HT3 receptor is a ligand-gated cation channel located in the central and peripheral nervous system; it has also been detected on a variety of other cells. In the periphery, it is found on autonomic neurons and on neurons of the sensory and enteric nervous system. In the CNS, the 5-HT3 receptor has been localized in the area postrema, nucleus tractus solitarii, nucleus vaudatus, nucleus accumbens, amygdala, hippocampus, entorhinal, frontal, cingulate cortex, and in the dorsal horn ganglia. Further extraneuronal locations include among others lymphocytes, monocytes, and foetal tissue. 5-HT3 receptors modulate the release of neurotransmitters and neuropeptides like dopamine, cholecystokinin, acetylcholine, GABA, substance P, and serotonin itself. They have been demonstrated to be involved in sensory transmission, regulation of autonomic functions, integration of the vomiting reflex, pain processing and control of anxiety. While the physiologic functions of the 5-HT3 receptor are discrete and difficult to detect, it plays a key role in certain pathologic situations related to increased serotonin release. Clinical development of 5-HT3 receptor antagonists revealed a remarkable range of activities. 5-HT3 receptor antagonists do not modify any aspect of normal behaviour in animals or induce pronounced changes of physiological functions in healthy subjects. Clinical efficacy was shown for various forms of emesis like chemotherapy-induced, radiotherapy-induced, and postoperative emesis, diarrhoea-predominant irritable bowel syndrome, anxiety, chronic fatigue syndrome, alcohol abuse, and in pain syndromes such as fibromyalgia and migraine. Most recent data also suggest that 5-HT3 receptor antagonists are effective for the treatment of other rheumatic diseases such as rheumatoid arthritis, tendinopathies, periarthropathies, and myofascial pain. Other possible indications under discussion are chronic heart pain and bulimia. Unfortunately, experimental findings do not yet provide a homogenous conception of the significance of 5-HT3 receptors in all investigated fields; in nociception, for example, contradictory observations are still inadequately explained and complicated by bell-shaped dose-response curves. Further elucidation and better understanding of the serotonergic neuronal network remains a task for the next decade.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15515404

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  23 in total

Review 1.  Fibromyalgia: a rheumatologic diagnosis?

Authors:  Gerhard K M Endresen
Journal:  Rheumatol Int       Date:  2007-07-20       Impact factor: 2.631

2.  The tail wags the dog: possible mechanism for reverse allosteric control of ligand-activated channels.

Authors:  E Vardy; T Kenakin
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

Review 3.  Signalling in response to sub-picomolar concentrations of active compounds: Pushing the boundaries of GPCR sensitivity.

Authors:  Srgjan Civciristov; Michelle L Halls
Journal:  Br J Pharmacol       Date:  2019-04-05       Impact factor: 8.739

Review 4.  The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Authors:  Yang Won Min; Poong-Lyul Rhee
Journal:  Therap Adv Gastroenterol       Date:  2015-05       Impact factor: 4.409

5.  Differences in regional cerebral blood flow response to a 5HT3 antagonist in early- and late-onset cocaine-dependent subjects.

Authors:  Bryon Adinoff; Michael D Devous; Mark J Williams; Thomas S Harris; Susan E Best; Hongyun Dong; Tanya Zielinski
Journal:  Addict Biol       Date:  2012-03-28       Impact factor: 4.280

6.  The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens.

Authors:  Mei Huang; Anna R Felix; Dorothy G Flood; Chaya Bhuvaneswaran; Dana Hilt; Gerhard Koenig; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2014-05-09       Impact factor: 4.530

Review 7.  Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.

Authors:  Michelle C Janelsins; Mohamedtaki A Tejani; Charles Kamen; Anita R Peoples; Karen M Mustian; Gary R Morrow
Journal:  Expert Opin Pharmacother       Date:  2013-04       Impact factor: 3.889

8.  Spinal 5-HT3 receptors facilitate behavioural hypersensitivity induced by elevated calcium channel alpha-2-delta-1 protein.

Authors:  E Y Chang; X Chen; A Sandhu; C-Y Li; Z D Luo
Journal:  Eur J Pain       Date:  2012-10-12       Impact factor: 3.931

9.  5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells.

Authors:  M Yasuda; S Kato; N Yamanaka; M Iimori; K Matsumoto; D Utsumi; Y Kitahara; K Amagase; S Horie; K Takeuchi
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

10.  5-HT3 receptors promote colonic inflammation via activation of substance P/neurokinin-1 receptors in dextran sulphate sodium-induced murine colitis.

Authors:  Daichi Utsumi; Kenjiro Matsumoto; Kikuko Amagase; Syunji Horie; Shinichi Kato
Journal:  Br J Pharmacol       Date:  2016-04-21       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.